Extreme Prostate‐Specific Antigen Response to Infusional 5‐Flourouracil in Castrate‐Resistant Prostate Cancer
Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous‐infusion 5‐fluorouracil (5‐FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, me...
Saved in:
| Published in: | The oncologist (Dayton, Ohio) Vol. 23; no. 3; pp. 383 - 385 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
AlphaMed Press
01-03-2018
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous‐infusion 5‐fluorouracil (5‐FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate‐resistant prostate cancer. Baseline prostate‐specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5‐FU therapy. We hypothesized that prostate‐specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.
This article presents a case of a patient with prostate cancer who was near death and then responded remarkably to infusional 5‐FU. |
|---|---|
| Bibliography: | . Disclosures of potential conflicts of interest may be found at the end of this article ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Disclosures of potential conflicts of interest may be found at the end of this article. |
| ISSN: | 1083-7159 1549-490X |
| DOI: | 10.1634/theoncologist.2017-0450 |